PR Newswire·Oct 20, 2026, 4:10 PM ET

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in The Chemours Company to Contact Law Firm

On August 4, 2026, Chemours reduced full-year adjusted EBITDA guidance from $800 million–$900 million to $775 million–$825 million.
Management disclosed excess inventory of Opteon refrigerants created an oversupplied aftermarket channel heading into 2026.
Chemours stock fell $3.34 per share (18.63%) to close at $14.59 on August 5, 2026, following the announcement.
The company identified approximately $65 million in aftermarket sales that should have been allocated to the current year.
UBS downgraded Chemours from "Buy" to "Neutral" & reduced its price target by 37.9% citing overselling in 2025 & early 2026.
Morgan Stanley & J.P. Morgan also lowered their price targets for Chemours.
Fletcher Moore Law PLLC is investigating potential securities violations & seeking monetary damages, corporate governance reforms, & reimbursement.
Shareholders may contact Fletcher Moore at fletcher@fmoorelaw.com for representation on a contingency fee basis with no cost to investors.